High Expression of VSTM2L Induced Resistance to Chemoradiotherapy in Rectal Cancer through Downstream IL-4 Signaling

• Published in: Journal of immunology research 2021, Vol.2021, p.6657012-17
• Main Authors: Liu, Hao, Zhang, Zhenzhan, Zhen, Peilin, Zhou, Meijuan
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antibodies; Apoptosis; Biomarkers; Biopsy; Cancer; Cell growth; Cell Line, Tumor; Cell proliferation; Chemoradiotherapy; Chemoradiotherapy - statistics & numerical data; Chemotherapy; Colorectal cancer; Colorectal carcinoma; Committees; Datasets; Datasets as Topic; Disease-Free Survival; DNA damage; DNA repair; Down-Regulation; Drug Resistance, Neoplasm - immunology; Female; Gastric cancer; Gene expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic - immunology; Humans; Immunohistochemistry; Immunology; Interleukin 4; Interleukin-4 - metabolism; Male; Medical prognosis; Middle Aged; mRNA; Neoadjuvant Therapy - methods; Neoadjuvant Therapy - statistics & numerical data; Neoplasm Recurrence, Local - epidemiology; Neoplasm Recurrence, Local - genetics; Neoplasm Recurrence, Local - immunology; Neoplasm Recurrence, Local - prevention & control; Nerve Tissue Proteins - metabolism; Nucleotide sequence; Organoids; Patients; Proctectomy; Prognosis; Radiation therapy; Radiation Tolerance - immunology; Rectal Neoplasms - genetics; Rectal Neoplasms - immunology; Rectal Neoplasms - mortality; Rectal Neoplasms - therapy; Rectum; Sequence analysis; Signal Transduction - immunology; Statistical analysis; Western blotting
• ISSN: 2314-8861; 2314-7156
• DOI: 10.1155/2021/6657012

Background. Preoperative chemoradiotherapy (pCRT) is a common and essential therapeutic strategy for patients with locally advanced rectal cancer (LARC), but poor tumor response and therapeutic resistance to chemoradiotherapy have appeared usually among persons and affected those patients’ survival prognosis. The resistance to chemoradiotherapy in rectal cancer is difficult to predict. This study was aimed at evaluating the role of V-set and transmembrane domain containing 2 like protein (VSTM2L) in resistance to chemoradiotherapy in rectal cancer. Methods. Analysis of the GEO profiling datasets of rectal cancer patients receiving pCRT disclosed that VSTM2L as a candidate gene was significantly upregulated in nonresponders of rectal cancer with pCRT. The mRNA and protein expression of VSTM2L was detected by quantitate real-time PCR, western blotting, and immunohistochemistry in six rectal cancer biopsy tissues before pCRT. Furthermore, the rectal cancer patient-derived organoids were cultured to evaluate the association of VSTM2L expression and tumor response to CRT. Overexpression of VSTM2L in cancer cells treated with CRT was analyzed for the function of cell proliferation and viability, clone formation, DNA damage repair, and apoptosis ability. The GSEA and RNA-sequence analysis were used to find the downstream mechanism of VSTM2L overexpression in cells treated with CRT. Results. The mRNA levels of VSTM2L were significantly downregulated in normal rectal tissues compared to tumor tissues and were upregulated in nonresponders of rectal cancer patients receiving pCRT and positively correlated with poor survival prognosis from GEO datasets. High expression of VSTM2L was significantly associated with tumor regression after pCRT (P=0.030). Moreover, high expression of VSTM2L reduced γ-H2AX expression in rectal cancer patient-derived organoids treated with CRT. The overexpression of VSTM2L in colorectal cancer cells induced resistance to CRT via promoting cell proliferation and inhibiting apoptosis. The molecular mechanism revealed that the overexpression of VSTM2L induced resistance to CRT through downstream IL-4 signaling affecting the progress of cell proliferation and apoptosis. Conclusion. The high expression of VSTM2L induced resistance to CRT, and adverse survival outcomes served as a prognostic factor in patients with rectal cancer receiving pCRT, suggesting that VSTM2L high expression may be a potential resistant predictable biomarker for LARC patie